Perimenopausal Bone Loss Clinical Trial
Official title:
Alendronate to Prevent Perimenopausal Transition Bone Loss
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and
Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal
women, is effective in decreasing the rate of bone loss which often begins to increase in
the three to five years preceding the menopause (perimenopausal transition).
During the three to five years prior to the menopause, the rate of bone loss increases. One
way that physicians treat this is with oral contraceptive medication. However, the incidence
of complications from oral contraceptives after the age of 40 increases. Therefore, a
non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a
class of compounds called bisphosphonates. This study is being done to determine whether
Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal
transition.
n/a
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04942691 -
Prevention of Osteoporosis: Effects of Mini-trampoline Training on the Bone Remodeling
|
N/A | |
| Completed |
NCT00290212 -
Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause
|
Phase 2 |